BCYC · Bicycle Therapeutics PLC
Market Cap
$254.81M
Shares
69.81M
Volume · Oct 5
1.84M
Avg daily vol (3M)
362.11K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.38
Open$3.65
Day$3.33–3.70
52W close$3.38–8.87
Avg vol 30d396K
Short int3.3M · 4.8% float · 6.7d
Short vol67%
Last earningsOct 30, 2025
DataJan 2020–Oct 2026
Filing10-Q · Jul 30
Up next
filed Jul 30, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$61.20M
Trailing 12 months
Net income (TTM)
−$190.41M
Trailing 12 months
Revenue growth YoY
-78.5%
Year over year
Operating margin
-343.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-81.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
-60.4%
Trailing year
Short interest
4.8%
Latest settlement · 6.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−15%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−32%
trailing
YTD return
−52%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.77% of float · ▲ +1.5% MoM · 6.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
103 holders — mid 3-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+106%
Y/Y
EPS growth
−9%
Y/Y
Free cash flow
$-252.0M
Balance sheet
$495.7M
net cash
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 30, 2026
Annual operating expenses
· current plans
50%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.77% of float · ▲ +1.5% MoM · 6.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
103 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $9
vs 200-day avg -31%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCYC
this stock
Bicycle Therapeutics PLC
|
$254.81M | -52.3% | +105.8% | — | 4.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCYC | -8.3% | -20.3% | -32.1% | -8.2% | -52.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -8.1% | -19.8% | -44.3% | -9.1% | -65.1% |